NO20093592L - Medikament for behandling av diabetes - Google Patents
Medikament for behandling av diabetesInfo
- Publication number
- NO20093592L NO20093592L NO20093592A NO20093592A NO20093592L NO 20093592 L NO20093592 L NO 20093592L NO 20093592 A NO20093592 A NO 20093592A NO 20093592 A NO20093592 A NO 20093592A NO 20093592 L NO20093592 L NO 20093592L
- Authority
- NO
- Norway
- Prior art keywords
- medication
- diabetes
- treatment
- diabetic
- patients
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 1
- 230000001934 delay Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2007/070140 WO2008147417A1 (en) | 2007-05-31 | 2007-05-31 | Method of treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20093592L true NO20093592L (no) | 2010-01-20 |
Family
ID=38812044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20093592A NO20093592L (no) | 2007-05-31 | 2009-12-23 | Medikament for behandling av diabetes |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2152268A1 (ko) |
| JP (1) | JP2010528112A (ko) |
| KR (1) | KR20100038322A (ko) |
| CN (1) | CN101678017A (ko) |
| AU (1) | AU2007354300A1 (ko) |
| BR (1) | BRPI0721741A2 (ko) |
| CA (1) | CA2687381A1 (ko) |
| IL (1) | IL202002A0 (ko) |
| MX (1) | MX2009012957A (ko) |
| NO (1) | NO20093592L (ko) |
| WO (1) | WO2008147417A1 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1505977B1 (en) | 2002-05-21 | 2014-09-10 | Gilead Sciences, Inc. | Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes |
| US8822473B2 (en) | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| RU2691620C1 (ru) * | 2018-11-26 | 2019-06-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) | Способ прогнозирования риска развития ишемической болезни сердца у пациентов с сахарным диабетом 2 типа в сочетании с субклиническим тиреотоксикозом |
| CN110812344A (zh) * | 2019-12-17 | 2020-02-21 | 卓和药业集团有限公司 | 一种治疗糖尿病合并心绞痛的药物组合物及制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| EP1505977B1 (en) * | 2002-05-21 | 2014-09-10 | Gilead Sciences, Inc. | Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes |
| EP1841411A2 (en) * | 2005-01-06 | 2007-10-10 | Cv Therapeutics, Inc. | Sustained release pharmaceutical formulations comprising ranolazine |
-
2007
- 2007-05-31 KR KR1020097027359A patent/KR20100038322A/ko not_active Application Discontinuation
- 2007-05-31 AU AU2007354300A patent/AU2007354300A1/en not_active Abandoned
- 2007-05-31 CN CN200780053142A patent/CN101678017A/zh active Pending
- 2007-05-31 MX MX2009012957A patent/MX2009012957A/es not_active Application Discontinuation
- 2007-05-31 JP JP2010510275A patent/JP2010528112A/ja active Pending
- 2007-05-31 EP EP07797962A patent/EP2152268A1/en not_active Withdrawn
- 2007-05-31 CA CA002687381A patent/CA2687381A1/en not_active Abandoned
- 2007-05-31 WO PCT/US2007/070140 patent/WO2008147417A1/en active Search and Examination
- 2007-05-31 BR BRPI0721741-2A patent/BRPI0721741A2/pt not_active IP Right Cessation
-
2009
- 2009-11-09 IL IL202002A patent/IL202002A0/en unknown
- 2009-12-23 NO NO20093592A patent/NO20093592L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007354300A1 (en) | 2008-12-04 |
| EP2152268A1 (en) | 2010-02-17 |
| CN101678017A (zh) | 2010-03-24 |
| IL202002A0 (en) | 2010-06-16 |
| MX2009012957A (es) | 2010-03-03 |
| BRPI0721741A2 (pt) | 2013-02-13 |
| JP2010528112A (ja) | 2010-08-19 |
| CA2687381A1 (en) | 2008-12-04 |
| WO2008147417A1 (en) | 2008-12-04 |
| KR20100038322A (ko) | 2010-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhernakova et al. | Individual variations in cardiovascular-disease-related protein levels are driven by genetics and gut microbiome | |
| Xue et al. | Improved glycemic control and vascular function in overweight and obese subjects by glyoxalase 1 inducer formulation | |
| Graff et al. | Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment | |
| Gradman et al. | Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study | |
| Huang et al. | Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy | |
| WO2010049678A3 (en) | Treatment of energy utilization diseases | |
| Lanas et al. | Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study | |
| Hörnsten et al. | Improvements in HbA1c remain after 5 years–a follow up of an educational intervention focusing on patients’ personal understandings of type 2 diabetes | |
| HK1136943A1 (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
| MX2010013876A (es) | Agonistas de arilo grpr119 y sus usos . | |
| NO20093592L (no) | Medikament for behandling av diabetes | |
| Zhang et al. | Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial | |
| EP2217596B8 (en) | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 | |
| Reynolds et al. | Individualizing warfarin therapy | |
| ATE516300T1 (de) | Neuromedin-u-rezeptoragonisten und ihre verwendung | |
| WO2007024555A3 (en) | Electronic personal health record system | |
| WO2008108958A3 (en) | Benzimidazole derivatives and methods of use thereof | |
| TW200833688A (en) | Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders | |
| Davies et al. | An inherited variant in the gene coding for vitamin D‐binding protein and survival from cutaneous melanoma: a B io G eno MEL study | |
| Kreutz et al. | Cytochrome P450 3A4* 22, PPAR-α, and ARNT polymorphisms and clopidogrel response | |
| Pramyothin et al. | Type 2 diabetes in children and adolescents on atypical antipsychotics | |
| BR0311161A (pt) | Método de tratamento de diabetes | |
| Sebastian et al. | Cardiovascular-Kidney-Metabolic (CKM) syndrome: A state-of-the-art review | |
| Maiese | Diabetic stress: new triumphs and challenges to maintain vascular longevity | |
| Fokkens et al. | Structured primary care for type 2 diabetes has positive effects on clinical outcomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |